For osteoporosis, vitamin K2 studies use 180 µg/day MK-7 or 45 mg/day MK-4; dosing should align with your doctor and medications.
You’re here to find a clear daily amount. The answer sits in research, not hype. Two forms of K2 appear in trials: MK-4 and MK-7. Doses in those studies are very different, and the label on a bottle can add to the confusion. This guide pulls the ranges used in trials, explains how they were tested, and gives you a simple plan to talk through with your care team.
Daily K2 Amounts For Bone Loss: What Studies Use
Researchers have tried both a drug-level regimen and a supplement-level regimen. MK-4 (menatetrenone) in Japan is a prescription drug at gram-scale monthly totals, while MK-7 shows up in nutrition trials at microgram doses. Here’s a quick map of the forms, amounts, and what outcomes looked like.
| Form | Typical Study Dose | What The Data Shows |
|---|---|---|
| MK-4 (menatetrenone) | 45 mg/day, split 15 mg × 3 | Used as a drug in Japan; fracture and BMD data reported in postmenopausal women and some secondary groups. |
| MK-7 (menaquinone-7) | 180 µg/day | Three-year trials in postmenopausal women report slower age-related bone loss and changes in K-status markers. |
| Vitamin K (dietary baseline) | Adults often aim for ~90–120 µg/day total vitamin K from food | Baseline intake matters for clotting and general health; not a treatment dose for bone disease. |
How These Doses Came To Be
MK-4 at 45 mg/day grew out of dose-finding work and later drug studies in Japan. MK-7 at 180 µg/day comes from multi-year randomized trials in women after menopause. A few trials showed slower bone loss with MK-7, while others saw no clear edge on bone density. The mixed picture tells you to place K2 alongside proven care, not as a lone answer.
MK-4: High Dose, Drug Status In Japan
Menatetrenone at 45 mg/day is a pharmacy item there. It’s taken with meals, three times per day. Trials used that schedule in women with bone loss, steroid-treated groups, and some other settings. The dose is far above what you’d see on a supplement label, so this path needs a prescription and ongoing checks.
MK-7: Lower Dose, Long Half-Life
MK-7 stays in the body longer than short-chain forms. That’s why a daily microgram dose appears in trials. One well-known study ran 180 µg/day for three years in healthy women after menopause and tracked bone markers and strength indices. Other groups repeated the 180 µg/day setup with mixed outcomes on density but steadier changes in K-status markers.
Who A Daily K2 Plan Fits
A K2 plan makes the most sense when it sits inside a full bone plan: calcium from food, vitamin D to reach and hold a target blood level, muscle-loading exercise, fall-reduction habits, and medicines when needed. K2 can slot in once the basics are steady. People on blood thinners need special care with dosing and food patterns. Thyroid meds, some antibiotics, bile acid binders, and fat-malabsorption states can change how K vitamins behave, so a pharmacist check helps.
Plain-Language Ranges You’ll See On Labels
Most MK-7 products list 90–200 µg per capsule. Long-term trials picked 180 µg/day. MK-4 in supplement aisles often lands at 1–5 mg per capsule, which is not the same as the drug dose. The Japan drug regimen is 45 mg/day, which is far higher and needs medical oversight.
How To Pick A Target Dose
Start by matching your situation to what trials used. If you’re a postmenopausal adult without a K-related bleeding risk and you want a supplement-level plan, 180 µg/day of MK-7 mirrors the longer trials. If you live with diagnosed bone disease and want the MK-4 drug path, that sits at 45 mg/day and requires a prescription and monitoring. People on warfarin or similar meds need a doctor-set plan that keeps intake steady, with dose changes only under supervision.
Food First Still Matters
Leafy greens give you K1. Fermented foods like natto bring MK-7. Cheese and some animal foods contain short-chain K2. A steady diet keeps your baseline covered. Supplements layer on top when a clinician thinks you need more structure.
Why You’ll See Different Advice Online
Writers pick one trial and run with it. A fair read looks across trials, not just headlines. Some studies report slower bone loss with MK-7 at 180 µg/day, others report no change in bone density at major sites. That gap explains why many medical groups place K2 as an optional add-on rather than a stand-alone therapy.
What Peer-Reviewed Trials Report
Three-year work with MK-7 at 180 µg/day in healthy women after menopause reported smaller age-linked losses at some hip sites and changes in bone strength indices. A later three-year trial in women with low bone mass did not see a clear edge in bone density against placebo at the main sites. Both styles of study tracked vitamin K status markers that moved in the expected direction with MK-7. The mixed picture points to a nutrient that may help maintain bone over time in select groups, while not replace full medical care when a fracture risk score is high. That read of the data matches the way many clinics treat K2: a steady add-on for select adults who already have calcium intake, vitamin D levels, and exercise in good shape.
How K2 Fits With Other Bone Medicines
Many readers already take agents like alendronate, risedronate, zoledronic acid, denosumab, or hormone-based therapy. K2 can sit beside those agents when a prescriber agrees, with a steady daily dose and routine labs. The MK-4 drug path in Japan is itself a prescription therapy and often appears in care plans there. In regions where MK-4 is not a drug, most users who add K2 choose MK-7 at the supplement level to mirror the published trials. The shared goal is fewer losses over time, safer movement, and fewer falls. Care teams often value consistency more than chasing a higher number. Pick a dose, keep it steady, and log it on every clinic visit. If a new medicine arrives, bring the bottle so the team can scan for conflicts. Small habits like that keep plans smooth and cut surprises.
Safety, Interactions, And Smart Timing
K vitamins tie into clotting. People on warfarin need consistent intake and MD-managed changes. High-dose MK-4 drug therapy sits in that same safety lane and uses routine checks. Take K2 with a meal that contains fat to help absorption. Keep an eye on total calcium and vitamin D so the whole plan stays in balance.
When Not To Start
Skip a new K2 plan if you use warfarin, unless your prescriber writes a plan. Delay a start during active infection being treated with certain antibiotics that change gut flora and vitamin K handling. Pause during short GI flares with poor fat absorption. When in doubt, bring your supplement bottle to your next visit and ask for a quick review.
Authoritative Benchmarks You Can Trust
Public bodies set baselines for total vitamin K, and they point to food as the main source. The NIH Vitamin K fact sheet lists adult baseline targets and drug-interaction notes. EFSA’s opinion sets an adequate intake figure and explains why a classic RDA isn’t set for this vitamin. Use those pages to set food goals, check baseline needs, and match any supplement dose with your meds plan. That keeps intake steady and avoids swings that can confuse lab tests or dose adjustments.
Label And Absorption Tips
Pick MK-7 from a brand that states the exact microgram amount, the form, and a clear date stamp. Look for third-party testing. Take the capsule with a meal that includes olive oil, dairy, avocado, or nuts. Keep the dose the same on weekends and trips every day. Store bottles away from heat and light at home, since both degrade delicate compounds in oil-based capsules.
Evidence At A Glance
Below is a compact round-up you can scan before you pick a bottle or talk dose with your care team.
| Option | Daily Amount | Notes |
|---|---|---|
| MK-7 supplement | 180 µg/day | Used for three years in postmenopausal women; mixed BMD outcomes; changes in K-status markers reported. |
| MK-4 prescription | 45 mg/day | Japan drug regimen; fracture and BMD outcomes reported in trials; needs medical oversight. |
| Dietary vitamin K | ~90–120 µg/day from food | Baseline intake for general health; not a treatment dose for bone disease. |
Sample One-Week Habit Plan
This is a simple, daily pattern you can tailor with your clinician. It pairs diet, movement, and any K2 dose you pick from the ranges above.
Daily Pattern
Morning: weight-bearing steps or short power walk. Midday: dairy, canned fish with bones, or tofu for calcium. Evening: greens with oil, plus your K2 dose with the meal. Twice per week: resistance work for legs and hips. Bedtime: quick fall-prevention scan at home—clear rugs, night light, sturdy slippers.
What To Check At Follow-Ups
Ask for vitamin D blood levels, a med review for interactions, and a plan for bone density testing. Bring your exact supplement and dosage. Keep intake steady day to day.
Key Takeaways You Can Act On Today
MK-7 at 180 µg/day lines up with long-term supplement trials. MK-4 at 45 mg/day is a drug path used in Japan. A diet rich in leafy greens and fermented foods sets your base. Any plan lives next to calcium, vitamin D, strength work, and fall-risk fixes. People on warfarin or with fat-absorption issues need tailored dosing and supervision.
Method Notes And Limits
This guide reflects tested ranges, not a promise of fracture prevention for every reader. Trial outcomes differ by site and method. Some cohorts saw less bone loss; others saw little or no change in density. That’s why a K2 plan should sit inside a larger bone plan and not replace proven care.
Sources Readers Can Verify
Read the NIH fact sheet noted above for baselines and drug notes. Review EFSA’s opinion for the adequate intake and the rationale. Search for the three-year MK-7 trial in women after menopause if you want study-level detail. People asking about MK-4 drug dosing can look up Japanese menatetrenone labeling and clinical reviews. If a local prescriber offers that drug path, ask about monitoring and how it pairs with calcium and vitamin D.